MannKind falls after quarterly revenue miss
** Shares of drugmaker MannKind MNKD.O fall 6.7% to $3.32 premarket ** Company reports Q1 revenue of $90.2 million, missing analysts' average expectation of $106.6 million - data compiled by LSEG ** Says collaborations and services revenue decreased due to fewer units sold to partner United Therapeutics UTHR.O ** MNKD reports Q1 loss of 5 cents per share, compared with a 4-cent loss a year earlier ** Up to last close, shares down 37.2% this year (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug